Benefits Persist With Inavolisib in Breast Cancer
New findings from the phase 3 INAVO120 trial underscore the durable benefits of inavolisib added to standard therapy for PIK3CA -mutated hormone receptor–positive (HR+) human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer.
The drug, in combination with palbociclib and fulvestrant, was approved in October 2024 by the US Food and Drug Administration based on previously published progression-free survival benefits.
Now, mature overall survival (OS) results and longer follow-up strengthen evidence for the triplet combination, said lead author and oncologist, Nicholas C. Turner, MD, PhD, during a press conference for the American Society of Clinical Oncology (ASCO) 2025 annual meeting.
'Importantly, this is the first time that OS has been improved by a PI3 kinase pathway targeted drug…we delayed the time to chemotherapy by almost 2 years, and the adverse event profile was consistent with previous reports, with low inavolisib discontinuation rates due to adverse events,' said Turner.
The INAVO120 trial included 325 patients with HR+ HER2− advanced breast cancer and a PIK3CA -mutation who had either failed hormone therapy or progressed within 1 year.
Patients were randomized to either standard therapy consisting of palbociclib and fulvestrant (placebo, n = 164) or the triplet combination that included standard therapy plus inavolisib (n = 161).
With a median follow-up now up 34.2 months, the study showed a 33% reduction in the risk of death in the inavolisib arm, translating to an OS of 34 months compared with 27 months in the placebo group (stratified hazard ratio [sHR] 0.67; P = .0190), he reported, in the press conference.
'We also looked at an endpoint that is really important for patients, which is the time until they have to consider chemotherapy-based care, and this was substantially improved…with almost a 2-year delay on average, to the time of needing to have chemotherapy,' he said.
Specifically, while patients in the placebo group needed chemotherapy at a median of 12.6 months, this was delayed until 35.6 months in the inavolisib group (sHR, 0.43).
Additionally, the previously published primary endpoint of median progression-free survival, which strongly favored inavolisib after a follow-up of roughly 21 months, (15.0 vs 7.3 months, sHR 0.43; P < .001) was maintained with longer follow-up (17.2 vs 7.3 months; sHR, 0.42).
With the extended time on therapy, adverse events remained 'generally manageable,' said Turner, although he cautioned 'this is not a drug without side effects.'
In total, 90.7% of patients in the inavolisib arm, and 84.7% in the placebo arm had grade 3/4 adverse events. Hyperglycemia (any grade) was experienced by 63.4% of the inavolisib group and 13.5% of the placebo group, and adverse events leading to discontinuation occurred in 6.8% and 0.6% or trial participants in each of the groups, respectively.
Previously, attempts to combine PI3K inhibitors with CDK4/6 inhibitors were not possible because side-effects were much worse, explained Turner. But the specificity of inavolisib has decreased that risk.
'So, that maximizes your ability to hit PI3 kinase in the tumor while relatively sparing normal cells in the body and reducing side effects,' Turner said, during the press conference.
Commenting on the study, ASCO chief medical officer and spokesperson Judy Gralow, MD, said she was particularly impressed with the therapy's benefit on time to next chemotherapy.
'Delaying the need, in the metastatic setting, to go on chemotherapy by almost 2 years is certainly an outcome that matters to patients,' she said. 'It is clear that, at least in a majority of breast cancers at the time of recurrence, we should be testing for PIK3CA mutations, as well as other alterations that direct therapy.'
However, she cautioned that the triplet therapy is only indicated in a subset of PIK3CA -mutated HR+ HER2− advanced breast cancer: namely those who have progressed either during, or within a year of hormone therapy. 'So, this is not all comers, [such as] patients who had tumors that 5 years later, 7 years later, showed evidence of recurrence.'
Calling the study results 'a big step forward' for this patient group, Jane Lowe Meisel, MD, co-director, Breast Medical Oncology, at the Winship Cancer Institute of Emory University School of Medicine, Atlanta, said the study 'illustrates the importance of genomic testing at the time of diagnosis of hormone receptor–positive metastatic breast cancer, so that patients with PIK3CA mutations who qualify for this approach can be readily identified.'
Turner disclosed consulting or advisory roles with AstraZeneca, Exact Sciences, Gilead Sciences, GlaxoSmithKline, Guardant Health, Inivata, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Relay Therapeutics, Repare Therapeutics, and Roche. He also received research funding with AstraZeneca; Guardant Health; Inivata; Invitae; Merck Sharpe & Dohme; Natera; Personalis; Pfizer; and Roche.
Meisel disclosed consulting or advisory roles with AstraZeneca, GE Healthcare, Genentech, Novartis, Olema Oncology, Pfizer, Seagen, Sermonix Pharmaceuticals, and Stemline. She also disclosed research funding from AstraZeneca, Olema Oncology, Pfizer, Seagen, and Sermonix Pharmaceuticals.
Gralow disclosed having no conflicts of interest.
The study was funded by F. Hoffmann–La Roche and a grant (P30CA008748) to the Memorial Sloan Kettering Cancer Center.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Hundreds of people raise $84,000 for Pulmonary Fibrosis Foundation during annual walk in Pittsburgh
Hundreds of people gathered in Pittsburgh's Riverfront Park on Saturday for the Pulmonary Fibrosis Foundation's annual walk. Participants walked on a one or two-mile course in support of those living with pulmonary fibrosis, a group of progressive lung diseases that cause scarring in the lungs, which limits oxygen intake necessary for major organs to function. Pulmonary fibrosis currently affects more than 250,000 Americans, and 50,000 new cases are diagnosed each year, according to PFF. Organizers say individuals and teams from the Pittsburgh region raised more than $84,000 to advance research for a cure for the life-threatening disease. Download the FREE WPXI News app for breaking news alerts. Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
Yahoo
an hour ago
- Yahoo
Campus notes: June 22, 2025
Teagan Graham, Reading, graduated from the University at Buffalo, N.Y., with a bachelor's degree in health and human services/early childhood education. York College The following area students received degrees from York College of Pennsylvania: Master of education: Julianna Kusy, Kutztown; Isabelle Popoter, Spring Township. Master of science in nursing: Elyse Batson, Exeter Township. Bachelor of arts: Isabella Antos, South Heidelberg Township; Lauryn Johnson, Exeter Township; Isabella Hoeltzel, Leesport; Elizabeth Trumbore, Temple. Bachelor of business administration: Gabriel Trevena, South Heidelberg Township. Bachelor of science: Brett Reinert, Douglassville; Haley Akins, Markus Jeschonnek and Brianna Endy, Exeter Township; Alexander LaVerdure, Oley Township;. Bachelor of science in nursing: Morgan Sauers, Gilbertsville; Taryn Boyer, Temple. Items are supplied by the colleges involved.
Yahoo
an hour ago
- Yahoo
What's the difference between an extreme heat watch and warning?
States across the Central and Eastern U.S. are under extreme heat watches and warnings as the areas are facing "dangerous heat," according to the National Weather Service. "Though record high temperatures are expected in the coming days, the duration of the heat, as demonstrated by the numerous record warm morning lows, will make this period especially oppressive," the National Weather Service posted on X June 20. The weather service has issued extreme heat warnings for areas in over a dozen states, as they face the highest temperatures of the year so far. It also issued extreme heat watches in several states and Washington D.C., according to an advisory issued to the agency's website. Here's everything you need to know about the heat wave. Portions of the following states have been placed under an extreme heat warning, according to the National Weather Service: Indiana Iowa Massachusetts Michigan Minnesota Missouri Nebraska New York Ohio Pennsylvania Rhode Island South Dakota Vermont West Virginia Areas where dangerous heat is possible are placed under an extreme heat warning and are asked to prepare in case it happens. Areas where dangerous heat "is happening or about to happen" are placed under an extreme heat warning, according to the weather service. While areas that are placed on a watch are asked to reschedule any planned outdoor activities, people in areas placed under warnings are told to avoid any heavy activity and direct sunlight. People facing extreme heat should do the following, according to NWS: Drink plenty of fluids Stay in an air-conditioned room Stay out of the sun Check up on relatives and neighbors Do not leave young children and pets in unattended vehicles Wear lightweight and loose-fitting clothing outdoors Limit strenuous activities to early morning or evening The extreme heat could negatively impact people's health. "Heat-related illnesses increase significantly during extreme heat and high humidity events," according to the National Weather Service. The following factors increase the possibility of a heat-related illness, according to the National Park Service: High humidity High elevation Strenuous activity Age: Infants, young children and people over 65 are more susceptible to heat illness Pregnancy Obesity Heart disease Poor circulation Fever Mental illness Dehydration Sunburn Prescription drug and alcohol use There are multiple forms of heat illnesses, but heatstroke is the deadliest and most dangerous, according to the NPS. The following are symptoms of heatstroke, according to the Centers for Disease Control and Prevention: Body temperature of 103 degrees or higher Skins that is hot, red, dry or damp Fast, strong pulse Headache Dizziness Nausea Confusion Losing consciousness In the case of a heatstroke, the CDC recommends people do the following: Call 911 immediately Move the person suffering from heatstroke to a cool location Lower the person's body temperature with a cool cloth or bath Do not give the person suffering from a heatstroke water or anything to drink Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn, X, Instagram and TikTok: @juliamariegz, or email her at jgomez@ This article originally appeared on USA TODAY: What's the difference between an extreme heat watch and warning?
